STOCK TITAN
  1. Home
  2. Sec-filings
  3. GANX
  4. [424B5] Gain Therapeutics, Inc. Prospectus Supplement (Debt Securities)

[424B5] Gain Therapeutics, Inc. Prospectus Supplement (Debt Securities)

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
424B5

Filing content is currently unavailable.

Source: View Original Filing on SEC EDGAR

Stock GANX logo
Gain Therapeutics, Inc.

NASDAQ:GANX

GANX Rankings

#5029 Ranked by Market Cap
N/A Ranked by Dividends

GANX Latest News

Aug 12, 2025
Gain Therapeutics Reports Financial Results for Second Quarter 2025 and Provides Corporate Update
Jul 24, 2025
Gain Therapeutics to Present at BTIG Annual Virtual Biotechnology Conference
Jul 16, 2025
Gain Therapeutics Announces Pricing of $7.0 Million Public Offering
Jul 15, 2025
Gain Therapeutics Announces Proposed Public Offering
Jun 30, 2025
Gain Therapeutics Announces Completion of Target Enrollment in Phase 1b Clinical Study Evaluating GT-02287 in People With Parkinson’s Disease With or Without a GBA1 Mutation

GANX Latest SEC Filings

Aug 12, 2025
[10-Q] Gain Therapeutics, Inc. Quarterly Earnings Report
Aug 12, 2025
[8-K] Gain Therapeutics, Inc. Reports Material Event
Jul 17, 2025
[8-K] Gain Therapeutics, Inc. Reports Material Event
Jul 15, 2025
[424B5] Gain Therapeutics, Inc. Prospectus Supplement (Debt Securities)
Jun 30, 2025
[8-K] Gain Therapeutics, Inc. Reports Material Event

GANX Stock Data

71.54M
34.64M
3.64%
10.56%
0.7%
Biotechnology
Pharmaceutical Preparations
Link
United States
BETHESDA